$NPCE
Neuropace Inc Stock $npce

$npce Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000152828724000005 Filed on March 05, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$18.12M	$18.01M	$65.42M
YoY Change	25.23%	40.84%	43.72%
Cost Of Revenue	$4.781M	$4.467M	$17.30M
YoY Change	16.61%	12.07%	32.79%
Gross Profit	$13.34M	$13.55M	$48.12M
YoY Change	28.64%	53.87%	48.1%
Gross Profit Margin	73.62%	75.2%	73.56%
Selling, General & Admin	$15.10M	$13.22M	$54.52M
YoY Change	12.48%	-2.61%	6.19%
% of Gross Profit	113.2%	97.59%	113.29%
Research & Development	$5.784M	$5.377M	$20.78M
YoY Change	9.9%	5.66%	-5.32%
% of Gross Profit	43.35%	39.7%	43.18%
Depreciation & Amortization	$45.00K	$40.00K	$200.0K
YoY Change	-6.25%	-25.93%	-33.33%
% of Gross Profit	0.34%	0.3%	0.42%
Operating Expenses	$20.89M	$18.60M	$75.30M
YoY Change	11.75%	-0.35%	2.74%
Operating Profit	-$7.545M	-$5.051M	-$27.17M
YoY Change	-9.3%	-48.77%	-33.39%
Interest Expense	$2.258M	-$1.414M	$8.517M
YoY Change	14.91%	23.93%	13.12%
% of Operating Profit
Other Income/Expense, Net	$51.00K	$265.0K	-$315.0K
YoY Change	-106.24%	-281.51%	-6.53%
Pretax Income	-$8.925M	-$6.200M	-$32.96M
YoY Change	-13.98%	-44.37%	-30.0%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$8.925M	-$6.200M	-$32.96M
YoY Change	-13.98%	-44.37%	-30.0%
Net Earnings / Revenue	-49.24%	-34.42%	-50.38%
Basic Earnings Per Share	-$0.32		-$1.27
Diluted Earnings Per Share	-$0.32	-$0.23	-$1.27
COMMON SHARES
Basic Shares Outstanding	28.34M shares	26.28M shares	25.85M shares
Diluted Shares Outstanding	28.29M shares		25.85M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.95M	$66.45M	$66.45M
YoY Change	-12.82%	-14.15%	-14.15%
Cash & Equivalents	$13.00M	$18.06M	$18.06M
Short-Term Investments	$45.95M	$48.40M	$48.40M
Other Short-Term Assets	$2.262M	$2.737M	$2.737M
YoY Change	-12.9%	-12.02%	-12.02%
Inventory	$11.42M	$11.21M	$11.21M
Prepaid Expenses
Receivables	$11.63M	$12.31M	$12.31M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$84.25M	$92.72M	$92.72M
YoY Change	-6.55%	-5.11%	-5.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.048M	$1.003M	$14.41M
YoY Change	2.34%	-5.73%	-9.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.00K	$15.00K	$524.0K
YoY Change	-28.57%	-28.57%	6.94%
Total Long-Term Assets	$14.60M	$14.93M	$14.93M
YoY Change	-9.41%	-8.91%	-8.91%
TOTAL ASSETS
Total Short-Term Assets	$84.25M	$92.72M	$92.72M
Total Long-Term Assets	$14.60M	$14.93M	$14.93M
Total Assets	$98.85M	$107.7M	$107.7M
YoY Change	-6.98%	-5.66%	-5.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.268M	$2.332M	$2.332M
YoY Change	78.68%	8.62%	8.62%
Accrued Expenses	$7.290M	$11.18M	$12.81M
YoY Change	10.79%	50.8%	45.06%
Deferred Revenue	$900.0K	$1.100M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.11M	$16.23M	$16.23M
YoY Change	32.76%	47.86%	47.86%
LONG-TERM LIABILITIES
Long-Term Debt	$58.04M	$56.95M	$56.95M
YoY Change	7.76%	7.64%	7.64%
Other Long-Term Liabilities	$13.36M	$13.81M	$13.81M
YoY Change	-11.19%	-10.53%	-10.53%
Total Long-Term Liabilities	$58.04M	$56.95M	$70.77M
YoY Change	7.76%	7.64%	3.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.11M	$16.23M	$16.23M
Total Long-Term Liabilities	$58.04M	$56.95M	$70.77M
Total Liabilities	$84.51M	$87.00M	$87.00M
YoY Change	7.27%	9.67%	9.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$512.7M	-$503.8M
YoY Change	6.55%	6.99%
Common Stock	$29.00K	$28.00K
YoY Change	16.0%	12.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.34M	$20.65M	$20.65M
YoY Change
Total Liabilities & Shareholders Equity	$98.85M	$107.7M	$107.7M
YoY Change	-6.98%	-5.66%	-5.66%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$8.925M	-$6.200M	-$32.96M
YoY Change	-13.98%	-44.37%	-30.0%
Depreciation, Depletion And Amortization	$45.00K	$40.00K	$200.0K
YoY Change	-6.25%	-25.93%	-33.33%
Cash From Operating Activities	-$7.500M	-$3.341M	-$19.70M
YoY Change	-22.68%	-57.4%	-46.61%
INVESTING ACTIVITIES
Capital Expenditures	$104.0K	$32.00K	$173.0K
YoY Change	-21.21%	-68.63%	-71.31%
Acquisitions
YoY Change
Other Investing Activities	$2.500M	$3.500M	$23.20M
YoY Change	-75.49%	-61.11%	-4.92%
Cash From Investing Activities	$2.396M	$3.468M	$23.03M
YoY Change	-76.2%	-61.02%	-3.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$72.00K	8.214M	$8.127M
YoY Change	-128.24%	-6052.17%	1558.57%
NET CHANGE
Cash From Operating Activities	-$7.500M	-3.341M	-$19.70M
Cash From Investing Activities	$2.396M	3.468M	$23.03M
Cash From Financing Activities	$72.00K	8.214M	$8.127M
Net Change In Cash	-$5.060M	8.341M	$11.45M
YoY Change	-4500.0%	809.6%	-191.03%
FREE CASH FLOW
Cash From Operating Activities	-$7.500M	-$3.341M	-$19.70M
Capital Expenditures	$104.0K	$32.00K	$173.0K
Free Cash Flow	-$7.604M	-$3.373M	-$19.87M
YoY Change	-22.66%	-57.55%	-47.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001528287
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40337
CY2023	dei	Entity Registrant Name EntityRegistrantName	NEUROPACE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3550230
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 N. Bernardo Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Mountain View
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94043
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	237-2700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	NPCE
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	65900000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28344637	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers
CY2023	dei	Auditor Location AuditorLocation	San Jose, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18058000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6605000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	48396000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	70804000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12314000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7482000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11214000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9712000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2737000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3111000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	92719000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	97714000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1003000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1064000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13405000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14838000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	387000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	347000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000	usd
CY2023Q4	us-gaap	Assets Assets	107651000	usd
CY2022Q4	us-gaap	Assets Assets	114106000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2332000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2147000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11180000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7414000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1627000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1415000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1090000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16229000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10976000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	56954000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52913000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13814000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15440000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	86997000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	79329000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27823465	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27823465	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25045751	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25045751	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	25000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	524435000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	506713000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1108000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-503809000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-470853000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20654000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34777000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107651000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	114106000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	65421000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45520000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17299000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13027000	usd
CY2023	us-gaap	Gross Profit GrossProfit	48122000	usd
CY2022	us-gaap	Gross Profit GrossProfit	32493000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20778000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21946000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	51341000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-27174000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3050000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1578000	usd
CY2023	us-gaap	Interest Expense InterestExpense	8517000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7529000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-315000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-337000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32956000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47082000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-836000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32956000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47918000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.91
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25851813	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25851813	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24594784	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24594784	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	73503000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47082000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-836000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	894000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	59000	usd
CY2022	npce	Adjustments To Additional Paid In Capital Change In Early Exercise Liability AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability	-4000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8349000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34777000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32956000	usd
CY2023	npce	Oci Unrealized Loss Adjustment For Short Term Investment OCIUnrealizedLossAdjustmentForShortTermInvestment	1108000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	149000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	654000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	509000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7622000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20654000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32956000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47082000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9558000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8349000	usd
CY2023	us-gaap	Depreciation Depreciation	172000	usd
CY2022	us-gaap	Depreciation Depreciation	267000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	283000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	258000	usd
CY2023	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	1075000	usd
CY2022	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	874000	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	2683000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	1934000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1433000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2720000	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-315000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-356000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	196000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	243000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-24000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4850000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	391000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1698000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2133000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-381000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	792000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	240000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	647000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3768000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-15000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1090000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1415000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2104000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19701000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36869000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	173000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	603000	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	23200000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	24400000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23027000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23797000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	803000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	896000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	259000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	59000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	7888000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	305000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	347000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8127000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	490000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11453000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12582000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6727000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19309000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18180000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6727000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18058000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6605000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18180000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6727000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	4476000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4464000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	10700000	usd
CY2023	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	-1000	usd
CY2022	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	-4000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	69000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	124000	usd
CY2023	npce	Deferred Offering Costs Offset Against Additional Paid In Capital DeferredOfferingCostsOffsetAgainstAdditionalPaidInCapital	265000	usd
CY2022	npce	Deferred Offering Costs Offset Against Additional Paid In Capital DeferredOfferingCostsOffsetAgainstAdditionalPaidInCapital	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-503800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19700000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36900000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	66500000	usd
CY2023	npce	Debt Instrument Covenant Minimum Annual Net Revenue DebtInstrumentCovenantMinimumAnnualNetRevenue	45000000	usd
CY2023Q4	npce	Debt Instrument Covenant Minimum Cash And Cash Equivalents Required After Completion Of Ipo DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO	5000000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	300000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	400000	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	300000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	npce	Revenue Contractual Period RevenueContractualPeriod	P2Y
CY2023Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	12300000	usd
CY2022Q4	us-gaap	Contract With Customer Receivable After Allowance For Credit Loss Current ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent	7500000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1100000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the years ended December 31, 2023 and December 31, 2022, there were no customers that represented 10% or more of revenue. As of December 31, 2023 and December 31, 2022, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of comprehensive epilepsy centers, or CECs, and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div>
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	200000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	200000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Term ResearchAndDevelopmentArrangementWithFederalGovernmentTerm	P5Y
CY2021Q2	npce	Research And Development Arrangement With Federal Government Total Estimated Cost ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost	9300000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Estimated Cost For Subawards ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards	5500000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Approved Funding Year1 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1	800000	usd
CY2021Q2	npce	Research And Development Arrangement With Federal Government Approved Funding Subawards Year1 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1	400000	usd
CY2022Q3	npce	Research And Development Arrangement With Federal Government Approval For Funding Year2 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2	2600000	usd
CY2022Q3	npce	Research And Development Arrangement With Federal Government Approval For Funding Subawards Year2 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2	1600000	usd
CY2023Q2	npce	Research And Development Arrangement With Federal Government Approval For Funding Year2 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2	3000000	usd
CY2023Q2	npce	Research And Development Arrangement With Federal Government Approval For Funding Subawards Year2 ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2	1500000	usd
CY2023	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warranty</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty costs are accrued based on the Company’s best estimates when management determines that it is probable a charge or liability has been incurred and the amount of loss can be reasonably estimated. While the </span></div>Company believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates.
CY2023	us-gaap	Advertising Expense AdvertisingExpense	700000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	700000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4090000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2818000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	627000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16125000	usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	48396000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	64521000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6075000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	70804000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	76879000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	70800000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	71900000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1100000	usd
CY2023	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	1000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	100000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1523000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6497000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5371000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11214000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	9712000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8770000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9788000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7767000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8724000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1003000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1064000	usd
CY2023	us-gaap	Depreciation Depreciation	200000	usd
CY2022	us-gaap	Depreciation Depreciation	300000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9655000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5748000	usd
CY2023Q4	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	588000	usd
CY2022Q4	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	764000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	227000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	907000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	675000	usd
CY2023Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	11180000	usd
CY2022Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	7414000	usd
CY2022Q3	npce	Operating Lease Renewal Term OperatingLeaseRenewalTerm	P5Y
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2857000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2942000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3031000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3122000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3215000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5017000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20184000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4743000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15441000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1627000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13814000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2800000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2700000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.085
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2800000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2100000	usd
CY2022Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2400000	usd
CY2022Q3	npce	Purchase Obligation Minimum Increase Percentage In Next Two Years PurchaseObligationMinimumIncreasePercentageInNextTwoYears	0.10
CY2022Q4	npce	Indemnification Liability Officers And Directors IndemnificationLiabilityOfficersAndDirectors	0	usd
CY2023Q4	npce	Indemnification Liability Officers And Directors IndemnificationLiabilityOfficersAndDirectors	0	usd
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q1	npce	Debt Instrument Principal Payment Number Of Installment DebtInstrumentPrincipalPaymentNumberOfInstallment	1	installment
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2023	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6733868	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7076678	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3038970	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.61
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	690218	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.83
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	157447	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	125158	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.99
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3446583	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.61
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y21D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	695225	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.85
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	889968	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.17
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	663075	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2588765	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1623869	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.22
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2588765	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.51
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y2M1D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	900000	usd
CY2023Q4	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	30211	shares
CY2022Q4	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	78389	shares
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
CY2021Q2	npce	Employee Stock Purchase Plan Length Of Offering Period EmployeeStockPurchasePlanLengthOfOfferingPeriod	P6M
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.045
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.072
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.018
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.014
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9558000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8349000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9558000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8349000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	16000000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.019
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2023	npce	Effective Income Tax Rate Reconciliation Reserve For Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationReserveForUncertainTaxPositionsPercent	-0.003
CY2022	npce	Effective Income Tax Rate Reconciliation Reserve For Uncertain Tax Positions Percent EffectiveIncomeTaxRateReconciliationReserveForUncertainTaxPositionsPercent	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.233
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.268
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41864000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40884000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13069000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12088000	usd
CY2023Q4	npce	Deferred Tax Assets Research And Development Expenditures Capitalized For Tax DeferredTaxAssetsResearchAndDevelopmentExpendituresCapitalizedForTax	8271000	usd
CY2022Q4	npce	Deferred Tax Assets Research And Development Expenditures Capitalized For Tax DeferredTaxAssetsResearchAndDevelopmentExpendituresCapitalizedForTax	4563000	usd
CY2023Q4	npce	Deferred Tax Assets Property Plant And Equipment Inventory And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentInventoryAndIntangibleAssets	151000	usd
CY2022Q4	npce	Deferred Tax Assets Property Plant And Equipment Inventory And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentInventoryAndIntangibleAssets	159000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1633000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1180000	usd
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	5033000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	3850000	usd
CY2023Q4	npce	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	3958000	usd
CY2022Q4	npce	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	4442000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1718000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1521000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	75697000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68687000	usd
CY2023Q4	npce	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3436000	usd
CY2022Q4	npce	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3910000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3436000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3910000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72261000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	64777000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q1	npce	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs Increase Decrease DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease	8300000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7500000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12800000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1700000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1601000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1489000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	136000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	112000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	7000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1730000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1601000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32956000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47082000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25851813	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25851813	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24594784	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24594784	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.91
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.91
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5130881	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5471794	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001528287-24-000005-index-headers.html	Edgar Link	pending
0001528287-24-000005-index.html	Edgar Link	pending
0001528287-24-000005.txt	Edgar Link	pending
0001528287-24-000005-xbrl.zip	Edgar Link	pending
exhibit1012-irinaridleytra.htm	Edgar Link	pending
exhibit1016-microsystemste.htm	Edgar Link	pending
exhibit1019-greatbatchfirs.htm	Edgar Link	pending
exhibit1020-greatbatchseco.htm	Edgar Link	pending
exhibit231-consentofpricew.htm	Edgar Link	pending
exhibit311-certificationsf.htm	Edgar Link	pending
exhibit312-certificationsf.htm	Edgar Link	pending
exhibit321-certificationsf.htm	Edgar Link	pending
exhibit42-descriptionofsec.htm	Edgar Link	pending
exhibit97-incentivecompens.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
npce-20231231.htm	Edgar Link	pending
npce-20231231.xsd	Edgar Link	pending
npce-20231231_g1.jpg	Edgar Link	pending
npce-20231231_g10.jpg	Edgar Link	pending
npce-20231231_g11.jpg	Edgar Link	pending
npce-20231231_g12.jpg	Edgar Link	pending
npce-20231231_g13.jpg	Edgar Link	pending
npce-20231231_g2.jpg	Edgar Link	pending
npce-20231231_g3.jpg	Edgar Link	pending
npce-20231231_g4.jpg	Edgar Link	pending
npce-20231231_g5.jpg	Edgar Link	pending
npce-20231231_g6.jpg	Edgar Link	pending
npce-20231231_g7.jpg	Edgar Link	pending
npce-20231231_g8.jpg	Edgar Link	pending
npce-20231231_cal.xml	Edgar Link	unprocessable
npce-20231231_def.xml	Edgar Link	unprocessable
npce-20231231_g9.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
npce-20231231_pre.xml	Edgar Link	unprocessable
npce-20231231_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
npce-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NPCE
Neuropace Inc Stock $npce

2024 Q1 Form 10-K Financial Statement

#000152828724000005 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE Neuropace Inc Stock $npce

2024 Q1 Form 10-K Financial Statement

#000152828724000005 Filed on March 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE
Neuropace Inc Stock $npce